SCHEMBL30767162

SCHEMBL30767162

CCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=O)C(=O)O)C(C)C

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NOD1 Q9Y239 6/20 0.49
DPP7 Q9UHL4 4/20 0.47
DPP4 P27487 2/20 0.41
DPP8 Q6V1X1 2/20 0.41
DPP9 Q86TI2 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
SLC15A1 P46059 1/20 0.41
ERAP2 Q6P179 1/20 0.41
GNAI3 P08754 1/20 0.40
GNAO1 P09471 1/20 0.40
GNAI1 P63096 1/20 0.40
C3AR1 Q16581 1/20 0.39
RRM1 P23921 1/20 0.39
FURIN P09958 2/20 0.38
MME P08473 1/20 0.38
CTSD P07339 1/20 0.38
BACE1 P56817 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30767177 1.00 NOD1 (0.49) NOD1DPP7DPP4DPP8DPP9
SCHEMBL30942562 0.92 NOD1 (0.56) NOD1DPP7DPP4DPP8DPP9
SCHEMBL29594367 0.92 NOD1 (0.56) NOD1DPP7DPP4DPP8DPP9
SCHEMBL29580013 0.91 NOD1 (0.41) NOD1DPP7SMN1; SMN2C3AR1FURIN
SCHEMBL29371278 0.90 GNAI3 (0.44) NOD1DPP7DPP8DPP9GNAI3
SCHEMBL29533710 0.88 BACE1 (0.46) NOD1DPP4DPP8DPP9CTSD
SCHEMBL29376100 0.88 BACE1 (0.48) NOD1DPP4DPP8DPP9CTSD
SCHEMBL29388901 0.88 C3AR1 (0.41) NOD1C3AR1FURINCTSDBACE1
SCHEMBL30477363 0.88 BACE1 (0.46) NOD1CTSDBACE1
SCHEMBL29371801 0.87 GNPAT (0.41) NOD1C3AR1FURINCTSDBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034236-A1 NEW DRUG COMPLEX KOWA COMPANY, LTD. (JP) 2026-02-05 US disclosed
EP-4570272-A1 NEW DRUG COMPLEX KOWA COMPANY, LTD. (JP) 2025-06-18 EP disclosed
CN-119698305-A New pharmaceutical complex 兴和株式会社 2025-03-25 CN disclosed
WO-2024034684-A1 NEW DRUG COMPLEX 興和株式会社 2024-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034236-A1 NEW DRUG COMPLEX OPRM1, ABCC1, OPRD1 NOD1 863/4885DPP7 3731/4885DPP4 3918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.